A citation-based method for searching scientific literature

Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews, Bruce Neal. Lancet Diabetes Endocrinol 2018
Times Cited: 239



Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann, Waheed Jamal, Karen Kimura, Janet Schnee, Cordula Zeller, Daniel Cotton, Edimar Bocchi, Michael Böhm, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure, Nadia Giannetti, Stefan Janssens, Jian Zhang, Jose R Gonzalez Juanatey, Sanjay Kaul, Hans-Peter Brunner-La Rocca, Bela Merkely, Stephen J Nicholls, Sergio Perrone, Ileana Pina, Piotr Ponikowski, Naveed Sattar, Michele Senni, Marie-France Seronde, Jindrich Spinar, Iain Squire, Stefano Taddei, Christoph Wanner, Faiez Zannad. N Engl J Med 2020
Times Cited: 615




List of shared articles



Times cited


Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun.
Pantelis Sarafidis, Alberto Ortiz, Charles J Ferro, Jean-Michel Halimi, Reinhold Kreutz, Francesca Mallamaci, Giuseppe Mancia, Christoph Wanner. J Hypertens 2021
3

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
Avivit Cahn, Itamar Raz, Lawrence A Leiter, Ofri Mosenzon, Sabina A Murphy, Erica L Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L Bhatt, Darren K McGuire,[...]. Diabetes Care 2021
4

Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin.
Ricardo Fontes-Carvalho, Diogo Santos-Ferreira, Itamar Raz, Nikolaus Marx, Frank Ruschitzka, Francesco Cosentino. Eur J Prev Cardiol 2021
1

GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.
Thomas Karagiannis, Apostolos Tsapas, Eleni Athanasiadou, Ioannis Avgerinos, Aris Liakos, David R Matthews, Eleni Bekiari. Diabetes Res Clin Pract 2021
4

Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
Takashi Kadowaki, Fumiko Yamamoto, Yusuke Taneda, Yusuke Naito, Douglas Clark, Søren S Lund, Tomoo Okamura, Kohei Kaku. Expert Opin Drug Saf 2021
0

Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
0


From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A Leiter, Antonio Ceriello, Ralph A DeFronzo, Itamar Raz. Cardiovasc Diabetol 2021
3

Recent advances in new-onset diabetes mellitus after kidney transplantation.
Tess Montada-Atin, G V Ramesh Prasad. World J Diabetes 2021
0

Recent advances in pharmacological treatment of heart failure.
Massimo Iacoviello, Alberto Palazzuoli, Edoardo Gronda. Eur J Clin Invest 2021
2


Empagliflozin Inhibits IL-1β-Mediated Inflammatory Response in Human Proximal Tubular Cells.
Markus Pirklbauer, Sebastian Sallaberger, Petra Staudinger, Ulrike Corazza, Johannes Leierer, Gert Mayer, Herbert Schramek. Int J Mol Sci 2021
1

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
William G Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H Lund, Paul Dendale, Petar Seferovic, Giuseppe Rosano, Natalie Staplin,[...]. Eur J Heart Fail 2021
1


New progress in drugs treatment of diabetic kidney disease.
Junmin Wang, Hongjiao Xiang, Yifei Lu, Tao Wu, Guang Ji. Biomed Pharmacother 2021
0

CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS.
Gianluigi Savarese, Javed Butler, Lars H Lund, Deepak L Bhatt, Stefan D Anker. Cardiovasc Res 2021
0

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod, Ofri Mosenzon. Cardiovasc Diabetol 2021
2

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases.
Kai-Fan Tsai, Yung-Lung Chen, Terry Ting-Yu Chiou, Tian-Huei Chu, Lung-Chih Li, Hwee-Yeong Ng, Wen-Chin Lee, Chien-Te Lee. Antioxidants (Basel) 2021
0

Are All SGLT2 Inhibitors Created Equal?
L Parker Gregg, Sankar D Navaneethan. Clin J Am Soc Nephrol 2021
0

Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.
David Z I Cherney, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Robert Frederich, Mario Maldonado, Chih-Chin Liu, Jie Liu, Annpey Pong,[...]. Clin J Am Soc Nephrol 2021
1